Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony Mok(Chinese University of Hong Kong), Nelly Cherciu, Filiz Çay Şenler, Sayeuri Buddu, Osvaldo Rudy Aren(Dnipro State Medical University), Christian Caglevic, Alvydas Česas, Gregory M. Lubiniecki(Merck & Co., Inc., Rahway, NJ, USA (United States)), Igor Bondarenko(Dnipro State Medical University), Michiel Botha, Orest Andrusenko, Debra Kush(Merck & Co., Inc., Rahway, NJ, USA (United States)), Л. В. Болотина, Iveta Kudaba(Riga East University Hospital), Anna Alyasova, Myung‐Ju Ahn(Sungkyunkwan University), Grigory Adamchuk, Fernando Barata, Susanna Cheng, Carlos Alexandre Sydow Cerny, Ying Cheng(Jilin Province Tumor Hospital), Byoung Chul Cho(Yonsei University), Gilberto Lopes(University of Miami), António Araújo(Administração Regional de Saúde de Lisboa e Vale do Tejo), Dariusz M. Kowalski(The Maria Sklodowska-Curie National Research Institute of Oncology), Hugo R. Castro(Instituto do Câncer do Estado de São Paulo), Andrés F. Cardona(Addario Lung Cancer Medical Institute), Vichien Srimuninnimit(Siriraj Hospital), К. К. Лактионов(Russian Cancer Research Center NN Blokhin), Touch Ativitavas, Gilberto de Castro(Instituto do Câncer do Estado de São Paulo), Gongyan Chen, Özden Altundağ, Xi Chen, Jin Zhang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Kaoru Kubota(Nippon Medical School Hospital), Carlos H. Barrios(Eastern Cooperative Oncology Group), H.Z. Turna(Istanbul University-Cerrahpaşa), Carlos Beato, Daniel Betticher, Jianhua Chang(Shanghai Medical College of Fudan University), Per Bergström, Aurelia Alexandru, Keisuke Aoe(National Sanyo Hospital), Gee-Chen Chan, Oscar Avendaño
Cited by 3,328
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k